Art. -Nr.: HY-13677A

6-Mercaptopurine hydrate

Name: 6-Mercaptopurine hydrate
Brand: MedChemExpress
SKU: HY-13677A
Price: 24.00 USD
Availability: InStock
Rating: 5 (21 reviews)

(Synonyms: Mercaptopurine hydrate; 6-MP hydrate)

21 Cited Publications

Kundenbewertung

Based on 21 publication(s) in Google Scholar

6-Mercaptopurine hydrate (Mercaptopurine hydrate; 6-MP hydrate) is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive agent.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.89%
CAS. Nr.: 6112-76-1
Formel: C₅H₆N₄OS
Molecular Weight:170.19

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

6-Mercaptopurine hydrate Chemical Structure

CAS. Nr.: 6112-76-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (21)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

endogenous purines^[1]

In Vitro

6-Mercaptopurine hydrate (Mercaptopurine hydrate; 6-MP hydrate) induces NR4A3 transcriptional activity 1.6- to 11-fold (P<0.01) in a dose-responsive manner. It is found that 6-Mercaptopurine hydrate leads to a dose-dependent increase in NR4A3 protein levels.
6-Mercaptopurine hydrate treatment increases cell surface GLUT4 in both basal cells 1.8- to 3.6-fold (P<0.01) and insulin-stimulated cells 2.9- to 4.4-fold (P<0.01) over that in controls. It is also found that 6-Mercaptopurine hydrate increases phospho-AS160 significantly in a dose-responsive manner under both basal and insulin-stimulated conditions^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .

In Vivo

In the fetal telencephalons of the 6-Mercaptopurine hydrate (6-MP)-treated group, the S phase cell population increases at 36 and 48 h and returns to the control level at 72 h after treatment. The G2/M phase cell population begins to increase at 24 h, peaks at 36 h, decreases at 48 h, and finally returnes to the control level at 72 h. On the other hand, the sub-G1 phase cell population (apoptotic cells) begins to increase at 36 h, peaks at 48 h, and then decreases at 72 h^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 6112-76-1
Appearance Solid
Molecular Weight 170.19
Formel C₅H₆N₄OS
Color Light yellow to yellow
SMILES

S=C1NC=NC2=C1NC=N2.O
Synonyms

Mercaptopurine hydrate; 6-MP hydrate
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (21)

All WBIn Vivo Efficacy StudyCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Nat Commun

Identification of purine biosynthesis as an NADH-sensing pathway to mediate energy stress. [Abstract]

2022 Nov 17;13(1):7031. PMID: 36396642

6-Mercaptopurine hydrate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Nov 17;13(1):7031. [Abstract]

6-Mercaptopurine (6-MP; 300 µM; pretreatment for 2 h) significantly inhibits EcSTH-induced phosphorylation of AMPK and ACC1 in HeLa^{Tet-on EcSTH} and MDA-MB-231^{Tet-on EcSTH} cells.
Adv Sci (Weinh)

NADH-Reductive Stress Induced by Dihydrolipoamide Dehydrogenase Activation Contributes to Cuproptosis. [Abstract]

2025 Dec 5:e20444. PMID: 41346305

6-Mercaptopurine hydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Dec 5:e20444. [Abstract]

Viability of SH‐SY5Y cells treated with 500 µM CuSO₄ and 100 µM 6-Mercaptopurine (6-MP) , 400 µM AICAR for 24 h (n = 3, unpaired t‐test).
Adv Sci (Weinh)

Targeting Caveolin-1 in Multiple Myeloma Cells Enhances Chemotherapy and Natural Killer Cell-Mediated Immunotherapy. [Abstract]

2025 Jan;12(4):e2408373. PMID: 39630017

6-Mercaptopurine hydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jan;12(4):e2408373. [Abstract]

MM1S cells were treated with 6-Mercaptopurine (6-MP, 1.25-10 µM) or daidzin at the indicated concentrations for 48 h and the expression of CAV1 was detected using western blot. The results showed that 6-MP significantly inhibited the expression of CAV1 protein.

6-Mercaptopurine hydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jan;12(4):e2408373. [Abstract]

B‐NDG mice were inoculated with MM1S‐Luc cells and randomly divided into six groups (n = 5–7). After 11 days of inoculation, these mice were intraperitoneally injected with 6-Mercaptopurine (6-MP) (10-20 mg/kg), daidzin (30 mg/kg), or vehicle daily until day 67. After 15 days of inoculation, mice were intraperitoneally injected with bortezomib (0.5 mg/kg) three times a week until day 67. The distribution of MM1S‐Luc cells in these mice was measured at the indicated days after inoculation using a living imaging system.

6-Mercaptopurine hydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jan;12(4):e2408373. [Abstract]

B‐NDG mice were inoculated with MM1S‐Luc cells and randomly divided into six groups (n = 5–7). After 11 days of inoculation, these mice were intraperitoneally injected with 6‐MP (10-20 mg/kg), daidzin (30 mg/kg), or vehicle daily until day 67. After 15 days of inoculation, mice were intraperitoneally injected with bortezomib (0.5 mg/kg) three times a week until day 67. Kaplan–Meier curve showing mice survival. The results showed that 6-MP further promoted the bortezomib‐mediated survival of MM‐bearing mice.
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 15;6(4):102053. PMID: 40187357
Cell Death Dis

Histidine re-sensitizes pediatric acute lymphoblastic leukemia to 6-mercaptopurine through tetrahydrofolate consumption and SIRT5-mediated desuccinylation. [Abstract]

2024 Mar 14;15(3):216. PMID: 38485947
Pharmacol Res

Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway. [Abstract]

2024 Feb:200:107082. PMID: 38280440
ACS Environ Au

Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]

2025 Aug 5;5(6):573-582. PMID: 41277996
Int J Biol Macromol

circE2F1-encoded peptide inhibits circadian machinery essential for nucleotide biosynthesis and tumor progression via repressing SPIB/E2F1 axis. [Abstract]

2024 Sep 15;280(Pt 1):135698. PMID: 39288851
Cell Rep

Structural basis for the reversal of human MRP4-mediated multidrug resistance by lapatinib. [Abstract]

2025 Mar 25;44(4):115466. PMID: 40138312
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
Life Sci

A protective role of ECSIT in chemotherapy-induced intestinal mucositis by maintaining Lgr5+ intestinal stem cells and gut homeostasis. [Abstract]

2026 Mar 15:389:124236. PMID: 41611204
Int J Pharm

Physicochemical characterization and clinical evaluation of 3D-printed subdivided tablets of 6-Mercaptopurine with broad dosage variations. [Abstract]

2026 Mar 10:692:126648. PMID: 41644072
Commun Biol

Ferroptosis-related gene signature for predicting prognosis and identifying potential therapeutic drug in EGFR wild-type lung adenocarcinoma. [Abstract]

2024 Oct 30;7(1):1416. PMID: 39478024
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Cancers (Basel)

Association between Dysfunction of the Nucleolar Stress Response and Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia. [Abstract]

2022 Oct 19;14(20):5127. PMID: 36291909
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
Front Oncol

Hypoxanthine in the microenvironment can enable thiopurine resistance in acute lymphoblastic leukemia. [Abstract]

2024 Jul 19:14:1440650. PMID: 39099696
Oral Dis

2026 Jul 15. PMID: 42458720
bioRxiv

2026 Jul 7:2026.07.06.736733. PMID: 42465347
bioRxiv

2026 Jul 7.
Res Sq

2026 Jun 15.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (293.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.8758 mL

29.3789 mL

58.7579 mL

5 mM

1.1752 mL

5.8758 mL

11.7516 mL

10 mM

0.5876 mL

2.9379 mL

5.8758 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (14.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 3.33 mg/mL (19.57 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Sahasranaman S, et al. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67. [Content Brief]

[2]. Liu Q, et al. 6-Mercaptopurine augments glucose transport activity in skeletal muscle cells in part via a mechanism dependent upon orphan nuclear receptor NR4A3. Am J Physiol Endocrinol Metab. 2013 Nov 1;305(9):E1081-92. [Content Brief]

[3]. Kanemitsu H, et al. 6-Mercaptopurine (6-MP) induces cell cycle arrest and apoptosis of neural progenitor cells in the developing fetal rat brain. Neurotoxicol Teratol. 2009 Mar-Apr;31(2):104-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.8758 mL	29.3789 mL	58.7579 mL	146.8946 mL
	5 mM	1.1752 mL	5.8758 mL	11.7516 mL	29.3789 mL
	10 mM	0.5876 mL	2.9379 mL	5.8758 mL	14.6895 mL
	15 mM	0.3917 mL	1.9586 mL	3.9172 mL	9.7930 mL
	20 mM	0.2938 mL	1.4689 mL	2.9379 mL	7.3447 mL
	25 mM	0.2350 mL	1.1752 mL	2.3503 mL	5.8758 mL
	30 mM	0.1959 mL	0.9793 mL	1.9586 mL	4.8965 mL
	40 mM	0.1469 mL	0.7345 mL	1.4689 mL	3.6724 mL
	50 mM	0.1175 mL	0.5876 mL	1.1752 mL	2.9379 mL
	60 mM	0.0979 mL	0.4896 mL	0.9793 mL	2.4482 mL
	80 mM	0.0734 mL	0.3672 mL	0.7345 mL	1.8362 mL
	100 mM	0.0588 mL	0.2938 mL	0.5876 mL	1.4689 mL

Bioz

Keywords

6-Mercaptopurine hydrate

21 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

6-Mercaptopurine hydrate

Publications Citing Use of MedChemExpress (MCE) 6-Mercaptopurine hydrate